{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T08:50:18Z","timestamp":1789462218308,"version":"build-2803163510"},"reference-count":19,"publisher":"BMJ","issue":"2","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2020,12,23]]},"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:p>Recessive dystrophic epidermolysis bullosa (RDEB) is a multisystem inherited disorder associated with fragile skin, blister formation and poor wound healing. Patients with RDEB are at significantly increased risk of recurrent and aggressive cutaneous squamous cell carcinoma (cSCC) and because of their disease complexity, conventional therapies may not be possible. Recent advances in cancer immunotherapy have led to the successful use of immune checkpoint inhibitors (ICIs) in melanoma and other malignancies. However, the effects of ICIs in patients with cSCC and RDEB are currently unknown. A 30-year-old woman with RDEB and multiple unresectable cSCCs was found to have high tumour mutational burden and PD-L1 (programmed cell death-ligand 1) expression. She was started on an ICI, which yielded disease control and was well tolerated. Furthermore, her RDEB wounds improved. This case demonstrates successful use of immunotherapy for advanced cSCC in RDEB, a disease that is often challenging to treat with local therapies.<\/jats:p>","DOI":"10.1136\/bcr-2020-238966","type":"journal-article","created":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T11:00:41Z","timestamp":1614337241000},"page":"e238966","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":18,"title":["Successful use of immunotherapy to treat advanced cutaneous squamous cell carcinoma in recessive dystrophic epidermolysis bullosa"],"prefix":"10.1136","volume":"14","author":[{"given":"Tony","family":"Duong","sequence":"first","affiliation":[{"name":"The University of Arizona College of Medicine Phoenix, Phoenix, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra","family":"Wong","sequence":"additional","affiliation":[{"name":"The University of Arizona College of Medicine Phoenix, Phoenix, Arizona, USA"},{"name":"Medical Oncology, The University of Arizona Cancer Center, Phoenix, Arizona, USA"},{"name":"Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Barrett","sequence":"additional","affiliation":[{"name":"Tempus Labs Inc, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harper","family":"Price","sequence":"additional","affiliation":[{"name":"The University of Arizona College of Medicine Phoenix, Phoenix, Arizona, USA"},{"name":"Division of Dermatology, Phoenix Children's Hospital, Phoenix, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,2,26]]},"reference":[{"key":"2025082707450354000_14.2.e238966.1","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1001\/jamadermatol.2016.2473","article-title":"Epidemiology of inherited epidermolysis bullosa based on incidence and prevalence estimates from the National epidermolysis bullosa registry","volume":"152","author":"Fine","year":"2016","journal-title":"JAMA Dermatol"},{"key":"2025082707450354000_14.2.e238966.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.01.903"},{"key":"2025082707450354000_14.2.e238966.3","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/jdv.15967","article-title":"Incidence and mortality for cutaneous squamous cell carcinoma: comparison across three continents","volume":"33 Suppl 8","author":"Stang","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025082707450354000_14.2.e238966.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.09.035"},{"key":"2025082707450354000_14.2.e238966.5","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20225707","article-title":"Epidermolysis bullosa-associated squamous cell carcinoma: from pathogenesis to therapeutic perspectives","volume":"20","author":"Condorelli","year":"2019","journal-title":"Int J Mol Sci"},{"key":"2025082707450354000_14.2.e238966.6","doi-asserted-by":"publisher","DOI":"10.1016\/S1011-1344(01)00199-3"},{"key":"2025082707450354000_14.2.e238966.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra022137"},{"key":"2025082707450354000_14.2.e238966.8","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1038\/jid.2009.31","article-title":"The effect of having an affected parent or sibling on invasive and in situ skin cancer risk in Sweden","volume":"129","author":"Hussain","year":"2009","journal-title":"J Invest Dermatol"},{"key":"2025082707450354000_14.2.e238966.9","doi-asserted-by":"publisher","DOI":"10.1111\/j.0303-6987.2006.00516_1.x"},{"key":"2025082707450354000_14.2.e238966.10","doi-asserted-by":"publisher","DOI":"10.1111\/j.0303-6987.2006.00516.x"},{"key":"2025082707450354000_14.2.e238966.11","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.26797"},{"key":"2025082707450354000_14.2.e238966.12","unstructured":"U.S. Food and Drug Administration (FDA) . Pd-L1 IHC 22C3 pharmDx. summary of safety and effectiveness data. Available: https:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf15\/P150013S006b.pdf [Accessed 20 Dec 2020]."},{"key":"2025082707450354000_14.2.e238966.13","doi-asserted-by":"crossref","DOI":"10.4103\/jpi.jpi_24_19","article-title":"Multi-field-of-view deep learning model predicts nonsmall cell lung cancer programmed death-ligand 1 status from whole-slide hematoxylin and eosin images","volume":"10","author":"Sha","year":"2019","journal-title":"J Pathol Inform"},{"key":"2025082707450354000_14.2.e238966.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805131"},{"key":"2025082707450354000_14.2.e238966.15","first-page":"871","article-title":"Review of cetuximab in the treatment of squamous cell carcinoma of the head and neck","volume":"3","author":"Merlano","year":"2007","journal-title":"Ther Clin Risk Manag"},{"key":"2025082707450354000_14.2.e238966.16","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30607-1"},{"key":"2025082707450354000_14.2.e238966.17","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-016-0176-3"},{"key":"2025082707450354000_14.2.e238966.18","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1001\/jamadermatol.2016.5118","article-title":"Expression of programmed cell death ligand in cutaneous squamous cell carcinoma and treatment of locally advanced disease with pembrolizumab","volume":"153","author":"Stevenson","year":"2017","journal-title":"JAMA Dermatol"},{"key":"2025082707450354000_14.2.e238966.19","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12030738","article-title":"Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence","volume":"12","author":"Vaddepally","year":"2020","journal-title":"Cancers"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2020-238966","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T14:45:10Z","timestamp":1756305910000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2020-238966"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":19,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,2,26]]},"published-print":{"date-parts":[[2021,2]]}},"alternative-id":["10.1136\/bcr-2020-238966"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2020-238966","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2]]}}}